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Identification and pharmacokinetics of saponins 
in Rhizoma Anemarrhenae after oral administration to rats 
by HPLC-Q-TOF/MS and HPLC-MS/MS
Rhizoma Anemarrhenae is a well-known herbal medicine with 
saponins as its commonly regarded major bioactive compo-
nents. It is essential to classify the properties of saponins 
which are associated with their toxicity and efficacy. In this 
study, 25 compounds were identified by HPLC-Q-TOF/MS in 
the extract of Rhizoma Anemarrhenae and 8 saponins were 
detected in rat plasma by HPLC-MS/MS after oral admini-
stration of this extract. These were neomangiferin, mangi-
ferin, timosaponin E1, timosaponin E, timosaponin B-II, timo-
saponin B-III, timosaponin A-III and timosaponin A-I. A 
sensitive and accurate HPLC-MS/MS method was developed 
and successfully applied to a pharmacokinetic study of the 
abovementioned eight saponins after oral administration of 
the Rhizoma Anemarrhenae extract to rats. The method valida-
tion, including specificity, linearity, precision, accuracy, reco-
very, matrix effect and robustness, met the requirements of 
the intended use. The pharmacokinetic parameter, Tmax value, 
ranged from 2 to 8 h for these eight saponins whereas their 
elimination half-life (t1/2) ranged from 4.06 to 9.77 h, indicating 
slow excretion. The plasma concentrations of these eight 
 saponins were all very low, indicating a relatively low oral 
bioavailability. All these results provide support for further 
clinical studies.
Keywords: Rhizoma Anemarrhenae, saponin, identification, 
pharmacokinetics, HPLC-Q-TOF/MS, HPLC-MS/MS
Rhizoma Anemarrhenae, the dried rhizome of Anemarrhena asphodeloides, is a well- 
-known traditional herbal medicine in China, Korea, and Japan (1). As a typical herbal 
medicine, Rhizoma Anemarrhenae has been extensively used for the treatment of inflamma-
tory and other diseases, including cough, fever, allergies, Alzheimer’s disease and diabe-
tes (2–5). Modern pharmacological research has also revealed its antidepressant, antidia-
betic, anti-inflammatory, antiplatelet aggregation, and antipyretic effects (6, 7). Previous 
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polysaccharides, lignans, etc. (4, 5, 8, 9), among which steroidal saponins are commonly 
regarded as the major bioactive components (10). These components have been demon-
strated various pharmacological properties including blood coagulation (11), attenuation 
of senile dementia (12, 13), tumour progression (1), inflammation (4, 14–17), and osteopo-
rosis (18). It is worth noting that over-administering some saponins can also cause cardio-
vascular disorders and even death (19).
Several previous studies have investigated the pharmacokinetics of timosaponin B-II 
and timosaponin A-III, two important steroidal saponins in Rhizoma Anemarrhenae, and 
showed slow absorption and low bioavailability after administration (20, 21). However, 
few systematic studies have addressed the pharmacokinetic characteristics of the total 
saponins in Rhizoma Anemarrhenae after the administration of its saponin extract (22–24).
The aim of this study was to identify the main saponins in rat plasma after oral admi ni-
stration of Rhizoma Anemarrhenae saponin extract using high-performance liquid chromato-
graphy-tandem quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF/MS), and to 
elucidate their pharmacokinetic characteristics by high-performance liquid chromato-
graphy-tandem triple quadrupole mass spectrometry (HPLC-MS/MS). Wang et al. (25) have 
established this HPLC-TOF/MS method. Here we applied it to the identification of chemi-
cal components in Rhizoma Anemarrhenae asphodeloides saponin extract and those absorbed 
into the blood. Also, here, an HPLC-MS/MS method was developed, validated and applied 
the first time, for quantitation of 8 saponins in the extract before administration, and 
 afterward for the pharmacokinetic assays.
EXPERIMENTAL
Chemicals and reagents
Standards of neomangiferin, mangiferin, timosaponin E1, timosaponin E, timosapo-
nin B-II, timosaponin B-III, timosaponin AIII, timosaponin A-I and the internal standard 
(IS), carbamazepine, were obtained from the National Institute for the Control of Pharma-
ceutical and Biological Products (China). Their structures were fully characterized by nu-
clear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), and their 
purities were shown to be over 98.5 %.
Acetonitrile and methanol were of HPLC grade and were purchased from Honeywell 
(USA). HPLC-quality water was purified using a Milli-Q water purification system (Milli-
pore, USA). All other reagents were of analytical grade.
The crude drug Rhizoma Anemarrhenae was purchased from the Shanghai Huayu 
Medicine Corporation (China) and authenticated by Prof. L. N. Sun, School of Pharmacy, 
Second Military Medical University, Shanghai, China.
Preparation of Rhizoma Anemarrhenae saponin extract
The dried crude drug was ground in a laboratory mill. One hundred grams of Rhizoma 
Anemarrhenae powder was extracted by ultrasound sonication with 500 mL 70 % ethanol 
for 30 min and then refluxed for 2 h. After vacuum filtration, another 500 mL 70 % ethanol 
was added to filter residue for an additional 2 h of reflux extraction and filtered again. The 
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filtrates from the two extractions were mixed and concentrated to 100 mL (equivalent to 
1 g crude herb per mL) for intragastric administration.
To identify the chemical components in Rhizoma Anemarrhenae, 1 mL of the Rhizoma 
Anemarrhenae saponin extract was diluted with 25 mL methanol. After 30 min of ultra-
sound sonication, the sample was vacuum filtered and the filtrate was used for the identi-
fication of chemical components in Rhizoma Anemarrhenae.
Animals
Male Sprague–Dawley rats aged 8 weeks (220–250 g) were provided by the Experimen-
tal Animal Center of the Second Military Medical University (Shanghai, China). Sprague–
Dawley rats were bred in a breeding room at 22 ± 2 °C with 50 ± 10 % relative humidity and 
a 12-h dark-light cycle. All animal experimental procedures conformed to the European 
Community Guidelines for Animal Experimentation and Welfare. The animal experimen-
tation studies were approved by the Ethics Committee on Animal Research in Second Mili-
tary Medical University (Shanghai, China). Before the experiments, the animals underwent 
1 week of acclimatization with food and water provided ad libitum and were fasted with free 
access to water for 12 h prior to the oral administration. After finishing the animal experi-
ment, the rats were sacrificed by cervical dislocation under anesthesia.
Standard solutions
Stock solutions. – Standard stock solution for any of the eight saponins was prepared 
by accurately weighing and dissolving the respective standard and internal standard in 
acetonitrile at the concentration of 200 μg mL–1 for each saponin and 100 ng mL–1 for the 
IS, and stored at 4 °C.
Calibration standards and quality control samples. – A series of standard solutions was 
obtained by diluting the abovementioned standard stock solutions with acetonitrile. The 
calibration standards were prepared by spiking 20 μL of standard solutions and 180 μL of 
IS solution into 100 μL of blank rat plasma to obtain the concentrations of 2.5–250 ng mL–1 
for neomangiferin, mangiferin, timosaponin E1, timosaponin E, timosaponin B-III, 
timosaponin AIII and timosaponin A-I, and 5–500 ng mL–1 for timosaponin B-II. The mix-
ture was then centrifuged at 12000 rpm for 10 min. Then the supernatant was transferred 
into an injection vial and a 2-μL aliquot was injected into the HPLC-MS/MS system for 
analysis.
Quality control (QC) samples were prepared by spiking 20 μL of standard solutions 
and 180 μL of IS solution into 100 μL of blank rat plasma to obtain three concentrations of 
10, 50, 250 ng mL–1 for timosaponin B-II and 5, 25, 100 ng mL–1 for other 7 saponins. The 
mixture was centrifuged for 10 min at 12000 rpm and the 2-μL aliquot of the supernatant 
was injected.
HPLC-Q-TOF/MS
For the identification of chemical compounds in Rhizoma Anemarrhenae extract and in 
rat plasma, an Agilent 1290 ultra-high-performance liquid chromatography-tandem quad-
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rupole time-of-flight mass spectrometer (HPLC-Q-TOF/MS, Agilent Technology Co., USA) 
was used, which consisted of a quaternary pump, an on-line degasser, a well-plate auto-
sampler, a thermostatic column compartment and a 6210 TOF mass spectrometer. The chro-
matographic separations were performed at 30 °C on a Waters Xbridge C18 column (3.5 μm, 
3.0 × 100 mm, Waters, USA). The mobile phase consisted of (A) water/formic acid (100:0.1, 
V/V) and (B) acetonitrile/formic acid (100:0.1, V/V) with the following gradient elution: 0–3 
min, 18–22 % B; 3–8 min, 22–25 % B; 8–10 min, 25–40 % B; and 10–15 min, 40–60 % B. The 
flow rate was set at 400 μL min–1. The sample injection volume was 2 μL. The parameters 
of the ion source were as follows: acquisition mode, positive mode; capillary voltage 3500 
V; drying gas (N2) temperature 350 °C; drying gas flow rate, 10 L min−1; nebulizer gas (N2) 
pressure 241 kPa; the fragmentor voltage 180 V and skimmer voltage 60 V. Mass spectra in 
the full-scan mode were recorded between m/z 100 and 1200. Agilent MassHunter B4.0 
software was used for the control of equipment, data acquisition and analysis.
HPLC-MS/MS
For the pharmacokinetic study of eight saponins, an Agilent 1290 high-performance 
liquid chromatography triple quadrupole mass spectrometer (HPLC-MS/MS) was used, 
which consisted of a degasser, a G7120A binary pump, a G7167B autosampler and a G7116B 
thermostated column compartment. An Agilent 6470 triple quadrupole mass spectrometer 
equipped with standard AJS electrospray ionization (ESI Jet stream – positive ions) was 
coupled to the HPLC system. Chromatographic separation was performed on the Waters 
Xbridge C18 column (3.5 mm, 3.0 × 100 mm) at 30 °C. The mobile phase system was com-
posed of (A) 0.1 % (V/V) aqueous formic acid and (B) acetonitrile. The following gradient 
elution was used: 0–4 min, 5–95 % B and 4–8 min, 95 % B. The flow rate was 0.4 mL min–1 
and the analysis time was 8 min. An aliquot of 2 μL of the solution was injected into the 
HPLC-MS/MS system for analysis. The flow outlet was directed to the mass spectrometer. 
The mass scan mode was positive dynamic MRM (fragmentor 110 V, skimmer 60 V), and 
each pair of precursor and product transitions of the analytes was auto-optimized by 
HPLC-MS/MS. The precursor-to-product ion pairs were m/z 585.1→303.1 for neomangiferin, 
m/z 423.1→303.1 for mangiferin, m/z 937.5→775.5 for timosaponin E1, m/z 937.5→775.5 for 
timosaponin E, m/z 921.5→759.5 for timosaponin B-II, m/z 903.5→741.5 for timosaponin 
B-III, m/z 741.5→579.5 for timosaponin A-III, and m/z 579.5→417.3 for timosaponin A-I. The 
following MS/MS working parameters were used after optimization: drying gas tempera-
ture 350 °C, drying gas flow rate 10 L min–1, nebulizer gas pressure 275.8 kPa, sheath gas 
temperature 350 °C, sheath gas flow rate 11 L min–1 and capillary voltage 3.5 kV.
HPLC-MS/MS validation
Validation of the HPLC-MS/MS method was performed with respect to specificity, 
accuracy, precision, the limit of detection (LOD), the limit of quantification (LOQ), linearity 
and range, robustness and stability according to the International Conference on Harmo-
nisation (ICH) guidelines (26).
Method specificity was investigated by comparing eight different rat plasma samples 
after oral administration of saponin extract, with blank plasma.
For each analyte, the linearity range was tested by spiking the saponin and IS into 
blank plasma samples in the concentration range of 2.5 to 25 ng mL–1, and five independent 
runs were conducted.
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For each saponin, LOD and LOQ were calculated using calibration curve data follow-
ing the equations: LOD = 3.3 × SD/slope and LOQ = 10 × SD/slope, where SD is the standard 
deviation of the regression line.
The intra- and inter-day precision and accuracy of the method were determined by 
using QC samples at low, medium and high concentration for three consecutive days. Rat 
plasma standard solutions including 8 saponins were used. For each concentration, five 
replicates were prepared. The concentration of each saponin was calculated by using a 
calibration curve on the same testing day. The accuracy was evaluated as the mean devia-
tion from the theoretical value and expressed as a percentual relative error.
Three sets of samples (A–C) at low, medium and high concentrations were prepared 
for the evaluation of extraction recovery (RE) and matrix effect (ME), and each concentra-
tion was prepared in five replicates. Set A was prepared by diluting the working standard 
solutions with methanol, set B was composed of blank plasma and working standard solu-
tions spiked before protein precipitation, in set C the spiking of the working solutions in 
blank plasma was performed after protein precipitation. RE and ME were evaluated by 
comparing the ratio of peak area of three sets of samples as follows: RE (%) = B/A × 100 and 
ME (%) = C/A × 100, where A, B and is the mean peak area ratio of saponin to IS of the re-
spective set. In short, RE of saponins was determined by comparing the peak areas ob-
tained from blank plasma spiked with analytes before the extraction with those from 
samples to which analytes were added after the extraction, whereas ME was assessed by 
comparing the blank plasma samples mixed with each saponin after the extraction process 
with the corresponding standard solution.
Robustness was evaluated by deliberate changes in chromatographic conditions such 
as the mobile phase flow rate (± 0.1 mL min–1), column temperature (± 2 °C), gas tempera-
ture (± 10 °C) and drying gas flow rate (± 1 mL min–1).
Stability was evaluated by analysing three QC samples at a low, medium and high 
level under different storage conditions. Short-term stability was measured by exposing 
the QC samples to room temperature for 24 h. Long-term stability was tested at –40 °C for 
30 days and freeze/thaw stability after three freeze-thaw cycles of the plasma samples.
Plasma samples and pharmacokinetic study
Six SD rats were intragastrically administered Rhizoma Anemarrhenae saponin extract 
at a dose equivalent to 10 g crude drug kg–1 rat. After drug administration, rat blood sam-
ples were collected into heparinized tubes via the caudal vein at 1, 2, 4 h and mixed finally. 
After centrifugation at 4000 rpm for 10 min, plasma samples were collected and a 100-μL 
aliquot of plasma sample was removed to a 1.5-mL polypropylene tube, 200 μL acetonitrile 
added and vortexed for 30 s. This mixture was centrifuged at 12000 rpm for 10 min. Then, 
the supernatant was transferred into an injection vial and a 2-μL aliquot was injected into 
the HPLC-Q-TOF/MS for identification of saponins in rat plasma.
Plasma samples for pharmacokinetic analyses were prepared as follows. Six male SD 
rats were given the saponin extract of Rhizoma Anemarrhenae (equivalent to 3 g crude drug 
kg–1 rat) per os. Blood samples (0.3 mL) were collected through the caudal vein into heparin-
ized tubes, before drug administration (time zero), and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 
36 and 48 h after drug administration. Plasma samples were centrifuged at 4000 rpm for 
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10 min, then collected and frozen at –40 °C until analysis by HPLC-MS/MS. To a 100-μL 
aliquot of plasma sample, 180 μL of the IS solution and 20 μL acetonitrile were added and 
vortexed for 30 s in a 1.5-mL polypropylene tube. The obtained mixture was then centri-
fuged at 12000 rpm for 10 min. After the supernatant was transferred into an injection vial, 
a 2-μL aliquot was injected into the HPLC-MS/MS system for the determination of eight 
saponins.
The pharmacokinetic parameters were calculated using DAS version 3.0 (BioGuider 
Co., China). A non-compartmental model was used to calculate the following parameters: 
maximum plasma concentration (Cmax) and time to attain Cmax (Tmax) were obtained  directly 
from the concentration-time curves. The elimination rate constant (k) was calculated by 
linear regression of the final linear part of the plasma concentration-time curve. The elimi-
nation half-life (t1/2) was calculated as 0.693/k. The area under the concentration-time curve 
(AUC0–t) was calculated using the linear trapezoidal rule. Mean residence time (MRT) was 
calculated from the formula MRT = AUMC0–∞/AUC0–∞, where AUMC0–∞ indicates the area 
under the first part of the plasma concentration-time curve. All the data are presented as 
the mean ± SD.
RESULTS AND DISCUSSION
Chemical composition of Rhizoma Anemarrhenae saponin extract
The HPLC-Q-TOF/MS chromatogram of Rhizoma Anemarrhenae saponin extract is 
shown in Fig. 1. By comparing three batches of raw Rhizoma Anemarrhenae with chemical 
components reported in the literature (10, 20, 27), 25 common peaks were confirmed (Table 
I), according to their retention time, accurate molecular mass and molecular formula.
The content of 8 saponins in the Rhizoma Anemarrhenae extract was determined by 
HPLC-MS/MS: neomangiferin 11.86 mg mL–1, mangiferin 14.69 mg mL–1, timosaponin E1 
9.56 mg mL–1, timosaponin E 3.15 mg mL–1, timosaponin B-II 40.85 mg mL–1, timosaponin 
B-III 2.32 mg mL–1, timosaponin A-III 11.03 mg mL–1, timosaponin A-I 3.26 mg mL–1.
Components in rat plasma after oral administration
By comparing retention time and the mass-to-charge ratio of ions with the identified 
components of Anemarrhena asphodeloides, eight major components were identified in rat 
plasma following oral administration of Rhizoma Anemarrhenae saponin extract. These 
were: neomangiferin, mangiferin, timosaponin E1, timosaponin E, timosaponin B-II, timo-
saponin B-III, timosaponin A-III and timosaponin A-I. Their molecular structures and 
mass ion spectra are shown in Figs. 2 and 3. They were also found in the chromatogram of 
the Rhizoma Anemarrhenae saponin extract in Fig. 1. A subsequent pharmacokinetic study 
on the eight active saponins was performed.
Development and validation of HPLC-MS/MS
Method development. – To achieve the best chromatographic separation, different mo-
bile phase compositions, as well as flow rates, chromatographic columns and column tem-
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peratures were investigated. Finally, an acetonitrile-water system containing 0.1 % (V/V) 
formic acid was selected as the mobile phase, as it achieved the best baseline. Better sepa-
ration and peak symmetry were achieved on a Waters Xbridge C18 column (3.5 mm, 3.0 × 
100 mm) than with other tested columns. By comprehensively considering the retention 
times and separation, the column temperature was set at 30 °C.
For the pharmacokinetic study, eight saponin standards were first tested in positive 
and negative modes. Finally, the positive mode was chosen, as all these compounds 
demonstrated stronger intensity in this mode than in the negative mode. An Agilent 
Fig. 1. HPLC-Q-TOF/MS chromatogram of 25 compounds identified in Rhizoma Anemarrhenae extract 
and eight saponins in rat plasma after oral administration. a) Eight saponins mixed standards; b) 
Rhizoma Anemarrhenae saponins extract, c) plasma sample after oral administration of Rhizoma Ane-
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 Automatic Optimizer was used to optimize the MS/MS method to achieve the highest 
 responses. Finally, the precursor transitions [M+H]+ were monitored.
Validation. – By analysing 8 different blank plasma samples, no interference of endo-
genous substances was observed for any of the saponins, indicating the good specificity of 
this method. Typical MRM chromatograms of blank plasma, blank plasma spiked with the 
Table I. Components identified in Rhizoma Anemarrhenae by HPLC-Q-TOF/MS
No. tR (min) Compound Formula Selected ion Expected m/z Detected m/z Error (ppm)
1 2.32 Neomangiferina C25H28O16 [M+H]+ 585.1456 585.1468 2.19
2 2.78 Mangiferina C19H18O11 [M+H]+ 423.0927 423.0919 –1.92
3 2.98 Isomangiferin C19H18O11 [M+H]+ 423.0927 423.0931 0.78
4 3.72 Timosaponin B-V C57H96O29 [M+H]+ 1245.6116 1245.6137 1.69
5 4.04 Timosaponin B-VI C58H98O29 [M+H]+ 1259.6272 1259.6293 1.66
6 4.48 Timosaponin H1 C56H92O28 [M+H]+ 1213.5853 1213.585 –0.24
7 4.67 Timosaponin I1 C56H94O28 [M+H]+ 1215.601 1215.6046 2.97
8 4.49 Timosaponin B-IV(C57) C57H94O28 [M+H]+ 1227.601 1227.5987 –1.87
9 5.1 Timosaponin I2 C57H96O28 [M+H]+ 1229.6166 1229.6193 2.18
10 5.47 Timosaponin H2 C57H94O28 [M+H]+ 1227.601 1227.6026 1.35
11 5.79 Timosaponin E1a C45H76O20 [M+H]+ 937.5008 937.5016 0.83
12 6.04 Timosaponin Ea C45H76O20 [M+H]+ 937.5008 937.5025 1.78
13 6.23 Timosaponin N C45H76O20 [M+H]+ 937.5008 937.5021 1.35
14 6.63 Timosaponin E2 C46H78O20 [M+H]+ 951.5165 951.5183 1.96
15 6.84 Macrostemonoside K C46H78O20 [M+H]+ 983.4885 983.4911 2.58
16 7.29 Timosaponin B-IIa C45H76O19 [M+H]+ 921.5059 921.5066 0.81
17 7.67 Timosaponin D C45H74O19 [M+H]+ 919.4903 919.4929 2.92
18 8.07 Timosaponin B-I C46H78O19 [M+H]+ 935.5216 935.5227 1.23
19 8.28 Timosaponin B-IIIa C45H74O18 [M+H]+ 903.4953 903.4964 1.18
20 9.62 Timosaponin F C39H64O15 [M+H]+ 773.4323 773.4311 –1.61
21 9.83 Anemarrhenasaponin I C39H66O14 [M+H]+ 759.4531 759.4522 –1.21
22 10.04 Anemarrhenasaponin Ia C40H68O14 [M+H]+ 773.4687 773.4703 2.03
23 10.35 Timosaponin G C39H64O14 [M+H]+ 757.4374 757.4372 –0.35
24 10.74 Timosaponin AIIIa C39H64O13 [M+H]+ 741.4425 741.4431 0.74
25 11.77 Timosaponin A-Ia C33H54O8 [M+H]+ 579.3897 579.389 –1.18
a Compound identified in rat plasma after oral administration.
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IS and a plasma sample from a rat administered by Rhizoma Anemarrhenae saponin extract 
are shown in Fig. 4.
As shown in Table II, the peak area ratios of each saponin to the IS were plotted against 
used concentrations. The coefficient of determination (R2) for each of these calibration 
curves was higher than 0.995, indicating a good linear detector response over the investi-
gated ranges. The LODs of the eight saponins ranged 0.81–1.62 ng mL–1, while the LOQs 
ranged from 2.46–4.92 ng mL–1, which indicated good sensitivity in rat plasma.
As shown in Table III, intra- and inter-day precision values were all within 1 and 10 %, 
as well as inaccuracy values through the respective relative error. er for the eight saponins 
ranged from –9.5 to 9.0 %, indicating acceptable accuracy of the method.
Fig. 2. Molecular structures of eight saponins detected in rat plasma: a) neomangiferin, b) mangi ferin, 
c) timosaponin E1, d) timosaponin E, e) timosaponin B-II, f) timosaponin B-III, g) timosaponin AIII, 
h) timosaponin A-I.
a)                                                                                b)
c)                                                                                d)
e)                                                                                f)
g)                                                                                h)
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Table IV shows that the absolute recovery for the eight saponins and IS ranged from 
85.0 to 95.0 %, suggesting that the recoveries of the eight saponins and IS were consistent. 
In addition, no significant differences of extract recovery were found among the three 
concentrations levels of 10, 50, 250 ng mL–1 for timosaponin B-II and 5, 25, 100 ng mL–1 for 
the other seven saponins, indicating that the recoveries of the eight saponins and IS were 
not concentration-dependent. Furthermore, the matrix effect of the analytes ranged from 
0 to 10 %.
The small deliberate changes of chromatographic conditions did not affect accuracy 
(recovery ranged 99.1–101.5 %), and hence the method was found robust (Table V).
The stability of saponins throughout processing and storage was comprehensively 
assessed for three different concentration levels, and five independent runs were per-
formed for each concentration. The ± er values for eight saponins were less than 10 %, indi-
Fig. 3. Mass spectra of eight saponins: a) neomangiferin, b) mangiferin, c) timosaponin E1, d) timosa-
ponin E, e) timosaponin B-II, f) timosaponin B-III, g) timosaponin AIII, h) timosaponin A-I.
a)                                                                                b)
c)                                                                                d)
e)                                                                                f)
g)                                                                                h)
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cating that the analytes were stable in rat plasma under the following storage conditions: 
short-term stability at room temperature for 24 h, long-term stability at –40 °C for 30 days, 
and after three freeze-thaw cycles. All data are shown in Table VI.
The HPLC-MS/MS chromatographic parameters obtained under final conditions are 
summarized in Table VII.
Fig. 4. HPLC-MS/MS chromatogram of eight saponins: a) blank plasma, b) eight saponins spiked in 
rat plasma, c) plasma sample after oral administration of Rhizoma Anemarrhenae extract. The com-
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Table II. Regression equation and correlation coefficient (R) for saponins in rat plasma (n = 5)
Analyte Linear range (ng mL–1) Standard curve R
LOD 
(ng mL–1)
Neomangiferin 2.5–250 y = 2.562x – 1.268 0.9963 0.81
Mangiferin 2.5–250 y = 3.051x – 1.451 0.9978 0.84
TimosaponinE1 2.5–250 y = 2.152x – 3.302 0.9947 0.82
Timosaponin E 2.5–250 y = 2. 145x – 3.558 0.9931 0.83
Timosaponin BII 5–500 y = 2.618x – 3.049 0.9949 1.62
TimosaponinBIII 2.5–250 y = 1. 683x – 1.852 0.9986 0.82
TimosaponinAIII 2.5–250 y = 2.017x – 3.041 0.9928 0.81
Timosaponin A-I 2.5–250 y = 1.211x – 1.817 0.9961 0.83
LOQ = 3×LOD














Neomangiferin 5.000 4.857 2.6 –2.9 4.945 9.0 –1.1
25.001 26.609 9.1 6.4 26.776 9.8 7.1
100.005 90.455 4.8 –9.5 91.200 1.4 –8.8
Mangiferin 5.001 5.220 6.5 4.4 4.699 7.4 –6.0
25.003 25.199 4.9 0.8 27.244 2.0 9.0
100.010 93.051 8.4 –7.0 107.599 7.4 7.6
Timosaponin E1 5.001 4.779 2.7 –4.4 4.838 3.1 –3.3
25.004 26.698 6.4 6.8 26.711 6.6 6.8
100.015 106.370 2.7 6.4 93.855 2.1 –6.2
Timosaponin E 5.000 4.931 1.4 –1.4 5.147 6.7 2.9
25.001 22.886 3.8 –8.5 24.829 8.7 –0.7
100.005 104.126 8.2 4.1 107.069 9.4 7.1
Timosaponin B-II 10.001 9.536 3.0 –4.6 10.447 2.6 4.5
50.004 52.468 9.1 4.9 47.874 8.3 –4.3
250.020 230.805 7.3 –7.7 240.708 8.2 –3.7
Timosaponin B-III 5.002 4.600 3.7 –8.0 4.944 9.1 –1.2
25.008 23.048 6.2 –7.8 27.070 7.2 8.2
100.015 105.203 5.9 5.2 103.712 2.6 3.7
Timosaponin AIII 5.003 5.151 7.2 3.0 5.030 2.0 0.6
25.013 27.001 9.1 8.0 24.114 6.5 –3.6
100.020 96.621 4.4 –3.4 106.723 5.0 6.7
Timosaponin A-I 5.001 4.869 1.7 –2.6 4.620 1.9 –7.6
25.005 25.885 5.8 3.5 24.054 9.7 –3.8
100.025 105.242 2.8 5.2 103.962 6.1 3.9
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Table IV. Matrix effect and extraction recovery of saponins and IS in rat plasma (n = 5)
Analyte Concentration (ng mL–1)
Matrix effect Extraction recovery

































































































































Internal standard  60.002 4.2 2.9 88.1 5.4



























Mobile phase flow rate 
0.3 mL min–1 100.9 99.4 100.1 100.4 100.3 99.5 100.9 99.4
0.5 mL min–1 100.8 100 99.1 100.1 101.1 100.3 100.8 100.0
Column temperature
28 °C 100.7 101.0 99.1 100.6 99.5 100.5 100.7 101.0
32 °C 99.1 100.9 99.5 101.4 99.7 100.8 99.1 100.9
Drying gas temperature
340 °C 100.9 101.5 100.3 99.3 99.1 99.6 100.9 101.5
360 °C 101.2 99.5 100.7 99.8 100.4 101.5 101.2 99.5
Drying gas flow rate
9 L min–1 100.7 101.0 99.1 100.6 99.5 100.5 100.7 101.0
11 L min–1 99.1 100.9 99.5 101.4 99.7 100.8 99.1 100.9
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Pharmacokinetic study after intragastric administration of Rhizoma Anemarrhenae 
saponin extract
Since eight saponins were detected in rat plasma after oral administration of Rhizoma 
Anemarrhenae saponin extract, their pharmacokinetic profiles in vivo were further investi-
gated by the use of the HPLC-MS/MS method. The pharmacokinetic profile of timosaponin 
AIII was determined up to 48 h after oral administration, whereas timosaponin E’ profile 
was determined up to 24 h due to the drop of the plasma concentration below LOQ 24 h after 
oral administration. The other six saponins were all determined up to 36 h after oral admini-
stration. The mean plasma concentrations in the concentration-time curves are shown in 
 Fig. 5. The mean pharmacokinetic parameter values were calculated by using DAS 3.0 based 
on the non-compartmental pharmacokinetic model and are summarized in Table VIII.
As shown in Fig. 5 and Table VIII, Tmax values of the eight saponins ranged from 2 to 
8 h, with timosaponin E1 with the lowest (Tmax 2.12 h) and timosaponin AIII the highest 












(ng mL–1) er (%)
Measured 
(ng mL–1) er (%)
Measured 
(ng mL–1) er (%)
Neomangiferin 5.000 4.824 –3.5 4.674 –6.5 5.263 5.3
25.001 24.395 –2.4 26.041 4.2 23.200 –7.2
100.005 106.791 6.8 98.045 –2.0 90.464 –9.5
Mangiferin 5.001 5.471 9.4 4.571 –8.6 5.378 7.6
25.003 24.557 –1.8 25.387 1.5 23.014 –8.0
100.010 106.742 6.7 102.267 2.3 109.088 9.1
Timosaponin E1 5.001 4.792 –4.2 4.852 –3.0 5.353 7.0
25.004 23.300 –6.8 26.745 7.0 23.876 –4.5
100.015 93.866 –6.1 98.127 –1.9 100.946 0.9
Timosaponin E 5.000 5.363 7.3 5.384 7.7 4.676 –6.5
25.001 25.210 0.8 23.333 –6.7 27.034 8.1
100.005 97.655 –2.3 94.291 –5.7 107.734 7.7
Timosaponin B-II 10.001 10.290 2.9 9.368 –6.3 9.262 –7.4
50.004 49.209 –1.6 51.374 2.7 47.028 –6.0
250.020 253.615 1.4 227.978 –8.8 266.853 6.7
Timosaponin B-III 5.002 4.678 –6.5 5.474 9.4 4.622 –7.6
25.008 26.937 7.7 25.378 1.5 25.692 2.7
100.015 102.201 2.2 104.269 4.3 99.680 –0.3
Timosaponin AIII 5.003 4.998 –0.1 4.789 –4.3 4.674 –6.6
25.013 25.257 1.0 26.039 4.1 25.338 1.3
100.020 95.411 –4.6 91.862 –8.2 90.821 –9.2
Timosaponin A-I 5.001 4.529 –9.4 4.598 –8.1 4.520 –9.6
25.005 26.859 7.4 25.488 1.9 22.996 –8.0
100.025 103.335 3.3 90.883 –9.1 107.383 7.4
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Fig. 5. Plasma concentration-time curves of eight saponins in rats after oral administration of Rhizoma 
Anemarrhenae saponin extract: a) neomangiferin, b) mangiferin, c) timosaponin E1, d) timosaponin E, 
e) timosaponin B-II, f) timosaponin B-III, g) timosaponin AIII, h) timosaponin A-I. Mean ± SD, n = 6.
a)                                                                               b)
c)                                                                               d)
e)                                                                               f)
g)                                                                               h)
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(Tmax 7.85 h) value. The Tmax values of the other six saponins were approximately 4 h. The 
elimination half-life (t1/2) of the eight saponins ranged from 4.06 to 9.77 h, with timosapo-
nin AIII showing the highest value (9.77 h), indicating a relatively long body residence time 
and slow excretion. The plasma concentrations of the eight saponins were very low, even 
for timosaponin B-II which dominated in the Rhizoma Anemarrhenae saponin extract, indi-
cating a relatively low oral bioavailability for these saponins.
CONCLUSIONS
In this paper, 25 compounds were identified in raw Rhizoma Anemarrhenae extract, and 
eight saponins were further detected in rat plasma after oral administration of the extract 
by HPLC-Q-TOF/MS. Then, a sensitive, specific and accurate HPLC-MS/MS method was 
developed, validated and effectively employed in quantitative analysis of eight saponins 
in the extract (neomangiferin, mangiferin, timosaponin, timosaponin, timosaponin B-II, 
timosaponin B-III, timosaponin A-III and timosaponin A-I) and in their pharmacokinetic 
study after oral administration to rats.
Pharmacokinetic parameter, Tmax, of the eight saponins ranged from 2 to 8 h; elimina-
tion half-life (t1/2) ranged from 4 to 10 h, indicating slow excretion. Concentrations of the 
saponins in plasma were all very low, indicating a relatively low oral bioavailability.
This is the first systematic study investigating the pharmacokinetic characteristics of 
Rhizoma Anemarrhenae saponins, therefore, we believe that the results from this research 
could provide meaningful guidance for future clinical research in pharmacodynamics, 
pharmacology and toxicology of this plant.
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